EZH2 and diffuse large B-cell lymphoma: Moreover, in addition to inhibits DLBCL cell growth in vivo through its enzymatic inhibition, EZH2 degradation with IHMT-337 inhibits the proliferation of TNBC primary patient cells and the formation of primary organoids.